comprehensive -WSS

comprehensive

author：comprehensive 2025-09-06 08:39:13 - browse：7932

green electrocardiogram scan. -- health tech coverage from STAT — Adobe

As Bristol Myers Squibb works to build its treatment for a heart condition that can cause difficulty breathing into a blockbuster drug, it’s propped up an algorithm designed to help find more people who are affected.

The algorithm, which is part of software developed by Viz.ai, earlier this month received clearance from the Food and Drug Administration. The tool, called Viz HCM, looks at 12-lead electrocardiograms collected during routine care and flags suspected cases of hypertrophic cardiomyopathy, or HCM, for further evaluation. As part of a multi-year agreement between the companies, BMS — whose drug, Camzyos, is used to treat HCM — provided funding and scientific input for the development of the algorithm.

“BMS has a vested interest in finding more patients with HCM,” said Matthew Martinez, a cardiologist who leads Viz.ai’s HCM medical advisory board. “Why? Because they’re so philanthropic? No, they want to sell more drugs. They want to help more people by identifying more people.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： The cancer stories no one wants to hear

hotspot

WSS

Eat, drink, but be wary — 4 foods that interact with medications

Flash flooding emergencies prompt evacuations in Kentucky, Tennessee

Tuesday set an unofficial record for the hottest day on Earth. Wednesday may break it.

Does Medicare's free annual wellness visit do any good?

Medicare slashes safety net hospital payments by nearly $1 billion

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Wikipedia

comprehensive

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

Group behind ProMed defends move to subscription

Psychedelics group wrestles with new pharma identity

Lifetime voting ban for felony convictions struck down in Mississippi

Psychedelics group wrestles with new pharma identity

Alnylam reports growth in sales of rare disease treatments

Moonlake's readout produced a cash windfall. Risks remain

Climate activists disrupt London Pride march to protest corporate sponsorship

Continuity nursing helped my family in our darkest PICU moments

FDA approves Sage Therapeutics’ rapid

explore

Does Medicare's free annual wellness visit do any good?

Pharma needs to include young adults in clinical research

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

CDC recommends RSV monoclonal antibody for infants

Calls for Trump's election interference trial to be televised part of long debate

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

hotspot

focus

explore

focus